Liquid biopsy technology may not be fully mature enough to deliver reliable results, according to two researchers at Johns Hopkins at Guardant Health . A comparison test to find mutations using Guardant360 by Guardant Health and PlasmaSELECT-R64 from Personal Genome Diagnostics produced results that exactly matched in two out of just three patients. "Liquid biopsy is a promising technology, with an exceptional potential to impact our ability to treat patients, but it is a new technology that may need more time and experience to improve," Torga said. Study lead author Christopher Furlong/Getty Images said the test demonstrated that "certification for these laboratories must improve".
Liquid biopsy technology may not be fully mature enough to deliver reliable results, according to two researchers at Johns Hopkins at Guardant Health . A comparison test to find mutations using Guardant360 by Guardant Health and PlasmaSELECT-R64 from Personal Genome Diagnostics produced results that exactly matched in two out of just three patients. Study lead author Christopher Furlong/Getty Images said the test demonstrated that "certification for these laboratories must improve".